Associated Papers
Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alteration.
Feng H et al.
Cancer Biology & Medicine, 2025
Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic.
Williams EA et al.
Acta Neuropathologica Communications, 2020
33087175 (PubMed )
Supplement: 40478_2020_1040_MOESM1_ESM.xlsx › Sheet1
MET-dependent solid tumours - molecular diagnosis and targeted therapy.
Guo R et al.
Nature Reviews. Clinical Oncology, 2020
A common MET polymorphism harnesses HER2 signaling to drive aggressive squamous cell carcinoma.
Kong LR et al.
Nature Communications, 2020
Status of Agents Targeting the HGF/c-Met Axis in Lung Cancer.
Miranda O et al.
Cancers, 2018
Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3.
Ross JS et al.
Cancer, 2018
29338072 (PubMed )
Supplement: CNCR-124-1358-s002.xlsx › Colon
Unexpected cancer-predisposition gene variants in Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome patients without underlying germline PTEN mutations.
Yehia L et al.
Plos Genetics, 2018
29684080 (PubMed )
Supplement: pgen.1007352.s010.xlsx › S9_Table
MET in human cancer: germline and somatic mutations.
Tovar EA et al.
Annals of Translational Medicine, 2017
Recurrent Mutations of Chromatin-Remodeling Genes and Kinase Receptors in Pheochromocytomas and Paragangliomas.
Toledo RA et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2016
Maxillary carcinosarcoma: Identification of a novel MET mutation in both carcinomatous and sarcomatous components through next generation sequencing.
Ando M et al.
Head & Neck, 2015
Functional consequence of the MET-T1010I polymorphism in breast cancer.
Liu S et al.
Oncotarget, 2015
The role of the c-Met pathway in lung cancer and the potential for targeted therapy.
Sattler M et al.
Therapeutic Advances in Medical Oncology, 2011
MET as a target for treatment of chest tumors.
Cipriani NA et al.
Lung Cancer (amsterdam, Netherlands), 2009
Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.
Ma PC et al.
Cancer Research, 2005
MET molecular mechanisms and therapies in lung cancer.
Lawrence RE et al.
Cell Adhesion & Migration, 0
Select a paper to view details